Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Corxel Pharmaceuticals · NCT06990867

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–90 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
740
US sites recruiting
20
Study start
May 15, 2025
Record last updated
September 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.

The main question the study aims to answer are:

  • JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS.
  • Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.

During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Being studied: JX10; Placebo

Conditions: Acute Ischemic Stroke

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age ≥ 18 and ≤ 90 years old.
  • Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA).
  • Radiographic evidence of salvageable tissue.
  • Pre-treatment score of NIHSS ≥ 5.

Exclusion Criteria

  • Radiographic findings pre-randomization of any of the following:
  • Large core infarction, or
  • Occlusion in more than 1 vascular territory, or
  • Significant mass effect or clinically significant cerebral edema, or
  • Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or
  • Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic.
  • Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding.
  • Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy.
  • Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \< 100,000/μL, international normalized ratio > 1.7, aPTT > 40 seconds, or prothrombin time > 15 seconds.
  • Major trauma, surgery, or invasive procedures.
  • Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study.
  • Pre-treatment blood glucose > 400 mg/dL (22.20 mmol/L) or Pre-treatment blood glucose \< 50 mg/dL (2.78 mmol/L) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement.

Recruiting US locations

  • Corxel Investigational Site

    Long Beach, CA 90806

    Site contact: Study Director · 201-268-3723 · Information.center@corxelbio.com

  • Corxel Investigational Site

    Los Angeles, CA 90048

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Sacramento, CA 95817

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Colorado Springs, CO 80909

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Washington D.C., DC 20007

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Delray Beach, FL 33484

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Chicago, IL 60616

    Site contact: Study Director

  • Corxel Investigational Site

    Wichita, KS 67214

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Baltimore, MD 21215

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Kalamazoo, MI 49048

    Site contact: Study Director · 201-268-3723 · Information.center@corxelbio.com

  • Corxel Investigational Site

    Traverse City, MI 49684

    Site contact: Study Director · 201-268-3723 · Information.center@corxelbio.com

  • Corxel Investigational Site

    St Louis, MO 63110

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Great Neck, NY 11021

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    New York, NY 10029

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Columbus, OH 43214

    Site contact: Corxel Investigational Site · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Toledo, OH 43606

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Tulsa, OK 74104

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Chattanooga, TN 37404

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Dallas, TX 75246

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Houston, TX 77030

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

Study contacts (from the official record)

  • Corxel Pharmaceuticals Study Information Center · 201-268-3723 · Information.center@corxelbio.com
All neurology studies in California →
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (NCT06990867) | Bored Studies